Eli Lilly and Company $LLY Shares Sold by Vision Capital Management Inc.

Key Points

• Vision Capital Management Inc. has decreased its stake in Eli Lilly by 22.1%, now holding 5,832 shares valued at approximately $4.5 million.
• Eli Lilly reported $6.31 EPS for the last quarter, exceeding estimates, with a 37.6% revenue increase year-over-year, totaling $15.56 billion.
• As of now, 82.53% of Eli Lilly's stock is owned by institutional investors and hedge funds, reflecting significant institutional interest in the company.

Vision Capital Management Inc. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 22.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,832 shares of the company's stock after selling 1,656 shares during the period. Vision Capital Management Inc.'s holdings in Eli Lilly and Company were worth $4,546,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. PNC Financial Services Group Inc. lifted its position in Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. GAMMA Investing LLC increased its holdings in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after buying an additional 14,852,076 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at about $4,613,912,000. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Finally, Cohen Investment Advisors LLC grew its position in shares of Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after purchasing an additional 773,947 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of LLY opened at $724.73 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The firm's 50 day moving average price is $734.15 and its 200 day moving average price is $767.20. The company has a market cap of $685.93 billion, a P/E ratio of 47.37, a PEG ratio of 0.99 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm earned $3.92 EPS. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on LLY. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Cantor Fitzgerald decreased their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Leerink Partners reiterated a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $939.61.

Insider Buying and Selling

In other news, Director Jamere Jackson acquired 200 shares of the company's stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.